Sigma-Aldrich 159026 Equivalent: Bulk Ribofuranose Tetraacetate
Technical Specifications and Purity Profiles: Contrasting Research-Grade Vial Parameters with Commercial Drum Requirements for Beta-D-Ribofuranose 1,2,3,5-Tetraacetate
When transitioning from research-grade reagents to bulk procurement, the first parameter under scrutiny is purity. Sigma-Aldrich 159026, typically supplied in 5 g or 25 g poly bottles, is specified at ≥98% purity by HPLC. For industrial-scale nucleoside synthesis, however, the conversation shifts from a simple percentage to a detailed impurity profile. Our bulk Beta-D-Ribofuranose 1,2,3,5-Tetraacetate (CAS 13035-61-5), also known as 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose, is manufactured to meet or exceed this benchmark, with typical batch purity reaching ≥99% (HPLC, area %). The critical difference lies in the consistency across metric-ton quantities. While a 5 g vial may exhibit minor lot-to-lot variation that is acceptable for exploratory chemistry, a 200 kg drum destined for a validated API process demands stringent batch-to-batch reproducibility. We achieve this through a controlled acylation route that minimizes the formation of partially acetylated species, which are common byproducts in less optimized processes. For detailed protocols on maintaining product integrity during scale-up, refer to our article on bulk crystallization handling protocols, which addresses a key non-standard parameter: the tendency of this protected ribose derivative to form amorphous solids under rapid cooling, impacting filtration and drying efficiency.
Heavy Metal Thresholds and Their Impact on API Synthesis: Comparing ≤20ppm vs ≤10ppm Limits in Bulk Ribofuranose Tetraacetate Sourcing
For procurement managers in the pharmaceutical sector, heavy metal content is a non-negotiable specification. Research-grade catalog products like Sigma-Aldrich 159026 often do not guarantee a specific heavy metal limit on the standard Certificate of Analysis, as the intended use is laboratory-scale synthesis. In contrast, our bulk Tetra-O-acetyl-β-D-ribofuranose is routinely tested for heavy metals (as Pb) and controlled to ≤20 ppm, with a premium grade available at ≤10 ppm upon request. This distinction is crucial when the downstream product is an active pharmaceutical ingredient (API) or an advanced intermediate. Residual palladium, iron, or nickel can catalyze unwanted side reactions during glycosylation or deprotection steps, leading to yield losses and challenging purifications. By sourcing a product with a defined and lower heavy metal specification, you mitigate the risk of batch failure during GMP production. This is a key aspect of our drop-in replacement strategy: we align our specifications not just with the catalog purity, but with the unspoken requirements of industrial users. The synthesis route we employ avoids metal catalysts entirely, relying on acid-catalyzed acetylation, which inherently results in lower metal contamination compared to routes using Lewis acid catalysts.
Batch-to-Batch HPLC Reproducibility and Trace Impurity Control: Mitigating Benzoyl Impurities from Alternative Acylation Routes
One of the most underappreciated challenges in scaling up protected ribose derivatives is the control of trace impurities that are invisible in a simple purity percentage. A common issue with alternative synthetic routes is the presence of benzoyl impurities when benzoyl chloride is used as an acylating agent. Our manufacturing process exclusively uses acetic anhydride, completely eliminating the risk of benzoylated ribofuranose contaminants. These impurities, even at 0.1%, can act as chain terminators in oligonucleotide synthesis or lead to difficult-to-remove byproducts in nucleoside analog production. Our HPLC methods are specifically developed to resolve and quantify these potential impurities, and every batch is released with a comprehensive impurity profile. We have observed that in some competitor samples, a shoulder peak eluting just after the main peak corresponds to a furanose-pyranose isomer, which can reach 0.5% if crystallization is not carefully controlled. Our in-house developed crystallization protocol, detailed in our glycosylation stereocontrol optimization guide, ensures that the anomeric purity is consistently >99.5%, a critical parameter for achieving high diastereoselectivity in subsequent Vorbrüggen glycosylation reactions.
| Parameter | Sigma-Aldrich 159026 (Typical) | Ningbo Inno Pharmchem Bulk Grade |
|---|---|---|
| Purity (HPLC) | ≥98% | ≥99% |
| Heavy Metals (as Pb) | Not routinely specified | ≤20 ppm (≤10 ppm on request) |
| Impurity Profile | Limited data | Full HPLC trace, <0.5% any single impurity |
| Anomeric Purity | Not specified | >99.5% β-anomer |
| Residual Solvents | Not specified | Compliant with USP <467> (Class 3) |
| Packaging | 5 g, 25 g poly bottle | 1 kg, 5 kg, 25 kg fiber drum; 210L steel drum |
Bulk Packaging and Supply Chain Considerations for Industrial-Scale Nucleoside Synthesis: From Poly Bottles to IBCs and 210L Drums
The logistics of moving from a 25 g poly bottle to a 25 kg fiber drum or a 210L steel drum involve more than just scaling the container size. Beta-D-Ribofuranose 1,2,3,5-Tetraacetate is a solid at ambient temperature, but it exhibits a relatively low melting point (81-83°C). In our field experience, during summer shipping in tropical climates, product in non-climate-controlled containers can reach temperatures where surface softening occurs, leading to caking or clumping. To mitigate this, we use double-layer packaging with a moisture-barrier bag inside the drum and recommend storage below 25°C. For large-volume users, we offer molten liquid filling into 210L steel drums under a nitrogen atmosphere, which simplifies handling at the receiving site if the product is to be dissolved directly in the process solvent. This is a practical, non-standard parameter that our logistics team can advise on. Our supply chain is designed for reliability, with safety stock maintained for regular customers to buffer against production scheduling fluctuations. We do not claim any specific environmental certifications, but our packaging is optimized for physical protection and ease of handling in a warehouse environment.
Quality Assurance and COA Parameters: Ensuring Seamless Drop-in Replacement for Sigma-Aldrich 159026 in Commercial Production
Validating a new bulk source against a research-grade benchmark requires a thorough comparison of Certificate of Analysis (COA) data. Our COA for every batch includes: appearance (white to off-white crystalline powder), identification (IR, NMR), purity (HPLC), melting point, heavy metals, loss on drying, and residual solvents. We encourage customers to request a sample and perform a head-to-head comparison in their specific process. A common validation protocol involves running a test glycosylation reaction with both the existing research-grade material and our bulk grade, then comparing the yield and purity of the isolated nucleoside. In most cases, the results are identical within experimental error, confirming the drop-in replacement capability. For GMP transition, we can provide additional documentation such as a Drug Master File (DMF) letter of authorization, stability data, and a statement of GMP compliance for our manufacturing facility. The cost-per-gram metric is where the value becomes undeniable: bulk pricing can reduce the raw material cost by 60-80% compared to catalog pricing, directly impacting the cost of goods for your API.
Frequently Asked Questions
How do I validate your bulk COA data against the Sigma-Aldrich 159026 certificate I have on file?
Start by comparing the HPLC method and column type. If both use a C18 reverse-phase column with UV detection at 210 nm, the purity numbers are directly comparable. Pay close attention to the integration parameters; we use area normalization. Request a sample and run it on your in-house HPLC system using your standard method. Overlay the chromatograms to identify any new or enlarged impurity peaks. Our technical support team can provide a detailed impurity identification report upon request.
What is an acceptable impurity profile for transitioning from research to GMP production of a nucleoside analog?
For early-phase GMP, any single unspecified impurity should be below 0.10% (ICH Q3A threshold for a drug substance dosed at ≤2 g/day). Since this intermediate is typically used in the first or second step of the synthesis, a slightly higher limit of 0.5% for any single impurity is often acceptable, provided the impurity is purged in downstream processing. The critical parameter is the absence of genotoxic impurities or impurities that carry through to the final API. Our process avoids the use of benzene or chlorinated solvents, minimizing this risk.
How does the cost-per-gram scale when moving from 25 g bottles to 25 kg drums?
The economy of scale is significant. While a 25 g bottle from a catalog supplier may cost several dollars per gram, bulk pricing for a 25 kg drum typically falls in the range of $0.50 to $1.50 per gram, depending on annual volume and purity requirements. For a pilot plant consuming 100 kg per year, this translates to a six-figure cost reduction. We provide formal quotations based on your projected annual usage.
Can you guarantee the anomeric purity, and why is it important for my glycosylation reaction?
Yes, we guarantee >99.5% β-anomer by NMR. The β-configuration is essential for the stereoselective synthesis of natural β-nucleosides via the Vorbrüggen method. The presence of the α-anomer leads to the formation of α-nucleoside impurities, which are difficult to separate and can compromise the biological activity of the final API. Our crystallization process is specifically designed to enrich the β-anomer.
What documentation do you provide for regulatory filings?
We can provide a Technical Package including the manufacturing process description, impurity fate and purge study, residual solvent statement, and a Letter of Authorization to reference our DMF. We also supply a GMP statement and can accommodate a quality audit of our facility.
Sourcing and Technical Support
As a global manufacturer specializing in carbohydrate and nucleoside intermediates, Ningbo Inno Pharmchem offers a reliable, cost-effective alternative to catalog suppliers for your bulk 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose needs. Our team of chemical engineers and quality specialists is available to discuss your specific technical requirements, from custom impurity specifications to tailored packaging solutions. We understand that a seamless transition requires more than just a competitive price; it demands technical equivalence, supply security, and responsive support. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.